The model allows for personalising PCa risks on the basis of a consultand's age, detailed cancer FH, moderate- to high-risk BRCA2, HOXB13, and BRCA1 PVs, and a 268-SNP PGS. This evidence concerns the gene BRCA2 and cancer.